Ivax, Lederle cefaclor AADA approvals spark Lilly suit over Ceclor process patents.
Executive Summary
IVAX, LEDERLE GENERIC CEFACLOR APPROVED BY FDA; LILLY FILES SUIT against Ivax/Zenith, Lederle, Biocraft and Biochimica April 27 alleging that bulk supplier Biochimica is infringing two of Lilly's Ceclor process patents. The approvals for Ivax and Lederle represent the first outside generic finished dosage form versions of the Lilly antibiotic.